[go: up one dir, main page]

PL3506923T3 - Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh - Google Patents

Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh

Info

Publication number
PL3506923T3
PL3506923T3 PL17846985.4T PL17846985T PL3506923T3 PL 3506923 T3 PL3506923 T3 PL 3506923T3 PL 17846985 T PL17846985 T PL 17846985T PL 3506923 T3 PL3506923 T3 PL 3506923T3
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical composition
fusion protein
growth hormone
hormone deficiency
Prior art date
Application number
PL17846985.4T
Other languages
English (en)
Inventor
Tae Kyung Kim
Jung Won Woo
Joan Yoon Ji LEE
Young-Joo Ahn
Ji-Eun CHA
Hyou Young RHIM
Woo Ick Jang
Original Assignee
Genexine, Inc.
Handok Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genexine, Inc., Handok Inc. filed Critical Genexine, Inc.
Priority claimed from PCT/KR2017/009471 external-priority patent/WO2018044060A1/en
Publication of PL3506923T3 publication Critical patent/PL3506923T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/61Growth hormones [GH] (Somatotropin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17846985.4T 2016-08-30 2017-08-30 Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh PL3506923T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160110806 2016-08-30
PCT/KR2017/009471 WO2018044060A1 (en) 2016-08-30 2017-08-30 PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN

Publications (1)

Publication Number Publication Date
PL3506923T3 true PL3506923T3 (pl) 2022-11-21

Family

ID=61726000

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17846985.4T PL3506923T3 (pl) 2016-08-30 2017-08-30 Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh

Country Status (15)

Country Link
US (1) US12427186B2 (pl)
EP (1) EP3506923B1 (pl)
JP (2) JP7333519B2 (pl)
KR (2) KR20180025269A (pl)
CN (2) CN110177567A (pl)
BR (1) BR112019004210A2 (pl)
CA (1) CA3034240C (pl)
DK (1) DK3506923T3 (pl)
ES (1) ES2926627T3 (pl)
HU (1) HUE059816T2 (pl)
JO (1) JOP20190019A1 (pl)
PL (1) PL3506923T3 (pl)
PT (1) PT3506923T (pl)
RU (1) RU2748402C2 (pl)
TW (4) TWI732713B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12233113B2 (en) 2016-02-17 2025-02-25 Genexine, Inc. Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency
CN114874333B (zh) * 2021-10-18 2025-01-24 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
MX2024006318A (es) 2021-11-26 2024-08-14 Genexine Inc Formulacion para administracion de alta concentracion de proteina de fusion de hormona del crecimiento.
CN115819611B (zh) * 2021-12-30 2024-05-28 君合盟生物制药(杭州)有限公司 生长激素融合蛋白及其制备方法和用途
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP2239273B1 (en) * 2003-11-13 2013-10-09 Hanmi Science Co., Ltd. A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
CN103356997A (zh) 2006-08-31 2013-10-23 诺瓦提斯公司 用于口服递送的包含hgh 的药物组合物
US7867491B2 (en) 2007-05-30 2011-01-11 Genexine Co., Ltd. Immunoglobulin fusion proteins
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질
NZ702557A (en) 2012-06-05 2017-06-30 Amunix Operating Inc Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
MX2015007402A (es) 2012-12-12 2015-09-23 Teva Pharma Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
KR20150124955A (ko) 2013-03-11 2015-11-06 아뮤닉스 오퍼레이팅 인코포레이티드 사람 성장 호르몬 유사체를 사용한 소아 성장 호르몬 결핍증의 치료 방법
KR20240110069A (ko) 2013-10-21 2024-07-12 옵코 바이오로직스 리미티드 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법
WO2016011281A1 (en) 2014-07-17 2016-01-21 Teva Pharmaceutical Industries Ltd. FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN
WO2016056812A1 (en) 2014-10-06 2016-04-14 Genexine, Inc. Human igg4 fc polypeptide variant
PL3220892T3 (pl) * 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
WO2017142331A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
US12233113B2 (en) 2016-02-17 2025-02-25 Genexine, Inc. Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency

Also Published As

Publication number Publication date
KR20180136418A (ko) 2018-12-24
CN118105512A (zh) 2024-05-31
EP3506923A4 (en) 2020-04-22
JP2019533004A (ja) 2019-11-14
JP2023061978A (ja) 2023-05-02
CN110177567A (zh) 2019-08-27
BR112019004210A2 (pt) 2019-09-10
TW201925237A (zh) 2019-07-01
JOP20190019A1 (ar) 2019-02-12
KR102309668B1 (ko) 2021-10-07
TW202120119A (zh) 2021-06-01
JP7333519B2 (ja) 2023-08-25
TW201806614A (zh) 2018-03-01
RU2019109154A (ru) 2020-10-01
TW201924714A (zh) 2019-07-01
TWI718334B (zh) 2021-02-11
PT3506923T (pt) 2022-09-07
RU2748402C2 (ru) 2021-05-25
US20190224281A1 (en) 2019-07-25
RU2019109154A3 (pl) 2020-12-30
EP3506923B1 (en) 2022-07-27
TWI732713B (zh) 2021-07-01
KR20180025269A (ko) 2018-03-08
DK3506923T3 (da) 2022-08-29
HUE059816T2 (hu) 2022-12-28
CA3034240A1 (en) 2018-03-08
CA3034240C (en) 2024-04-23
US12427186B2 (en) 2025-09-30
EP3506923A1 (en) 2019-07-10
ES2926627T3 (es) 2022-10-27

Similar Documents

Publication Publication Date Title
PL3865506T3 (pl) Białko fuzyjne do zastosowania w leczeniu choroby hvg
HUE051661T2 (hu) Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával
GB2564823B8 (en) Compositions and methods for TCR reprogramming using fusion proteins
EP3624846C0 (en) HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A MIXTURE OF NICOTINIC ACID AND TRYOPTOPHAN
ZA201802002B (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
IL250622B (en) Prepared sirp-alpha fusion proteins and pharmaceutical preparations containing them
DK3368555T3 (da) Dobbeltfunktionsproteiner og farmaceutisk sammensætning omfattende disse
HUE054201T2 (hu) PD-1-CD28 fúziós fehérjék és gyógyászatban való alkalmazásuk
EP3515420C0 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN BLEPHARITIS THERAPY
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
PL3506923T3 (pl) Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh
DK3915553T3 (da) Sammensætninger indeholdende aminosyrer til brug i behandlingen af mitokondrie-dysfunktion-relaterede neurodegenerative sygdomme
ZA201806357B (en) Protein based excipient for active pharmaceutical ingredients
EP3419651C0 (en) IMPROVED NAGLU FUSION PROTEIN FORMULATION
EP3362048A4 (en) COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS
ZA202007491B (en) Stable fusion protein formulation
SG11202104166QA (en) High concentration protein formulation
DK3416677T3 (da) Farmaceutisk sammensætning omfattende rekombinant hgh til behandlingen af væksthormonmangel
PT3257524T (pt) Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
EP3463327A4 (en) STABILIZATION OF BETA-HYDROXYISOVALERIC ACID FORMULATIONS IN SOFT CAPSULES
IL289219A (en) Composition and methods of stabilizing liquid protein formulations
HK40111802A (zh) 含有hgh融合蛋白的治疗生长激素缺乏症的药物组合物
EP3173422A4 (en) Pharmaceutical composition containing, as active ingredient, granulocyte-colony stimulating factor mutant protein or transferrin fusion protein thereof
TH1601000600A (th) โปรตีนการเชื่อมหลอมที่ใช้ในการรักษา